The Risk of Haemorrhage After Image Guided Stereotactic Biopsy of Intra-axial Brain Tumours--a Prospective Study
Overview
Authors
Affiliations
Objective: To analyze prospectively the frequency and the risk of symptomatic and asymptomatic haemorrhage after image guided stereotactic biopsy of intra-axial brain tumours.
Methods: The study was conducted within a time frame of 24 months (April 1998-April 2000). 326 patients (150 males, 176 females; mean age 56.8 years) were included and 345 computerized tomography (CT)-guided stereotactic biopsies were performed/supervised by a specialized stereotactic neurosurgeon. A modified Riechert Stereotaxy System and a workstation for multiplanar trajectory planning were used in all patients. Serial biopsies (median, 5 samples) were done with small forceps (diameter 1 mm), smear preparations of the biopsy specimens were intra-operatively examined. Frequency, size, and location of any detectable bleeding were analyzed by post-biopsy CT-scan investigation. For risk estimation, logistic regression analysis was performed. The chi-square statistic was used for comparative analysis of the study results with available data from the literature.
Results: A conclusive tissue diagnosis could be achieved in 98%. Overall treatment morbidity was 3.1%. There was no mortality. Haemorrhage related morbidity was 0.9%. Age, Karnofsky score, mass effect of the tumour, tumour histology, tumour location and the number of specimens taken did not have any prognostic significance. The clinically silent bleeding rate was 9.6% and more often seen in patients with high grade gliomas (p = 0.03). Both the silent and non-silent bleeding rate were significantly lower as compared to available prospective data in the literature (p < 0.01).
Conclusion: Using multiplanar image guided trajectory planning, small biopsy forceps and intra-operative smear preparations the risk of major haemorrhage related morbidity after stereotactic brain tumour biopsy is extremely low (<1%) in experienced hands.
Gu J, Huang X, Zhang Y, Bao C, Zhou Z, Tong H BMC Cancer. 2024; 24(1):1443.
PMID: 39578739 PMC: 11583561. DOI: 10.1186/s12885-024-13195-5.
Retrospective Evaluation of Cases Undergoing Stereotaxic Brain Biopsy.
Yolcu A, Akar E, Aker F, Emon S Asian J Neurosurg. 2023; 18(3):602-608.
PMID: 38152506 PMC: 10749858. DOI: 10.1055/s-0043-1774821.
Niedermeyer S, Terpolilli N, Nerlinger P, Weller J, Schmutzer M, Quach S Acta Neurochir (Wien). 2023; 165(12):4071-4079.
PMID: 37676505 PMC: 10739544. DOI: 10.1007/s00701-023-05768-3.
Sharma M, Do T, Palzer E, Huling J, Chen C J Neurooncol. 2023; 162(1):147-156.
PMID: 36920678 DOI: 10.1007/s11060-023-04275-w.
Advances, technological innovations, and future prospects in stereotactic brain biopsies.
Bex A, Mathon B Neurosurg Rev. 2022; 46(1):5.
PMID: 36471144 PMC: 9734929. DOI: 10.1007/s10143-022-01918-w.